FibroBiologics, Inc. SEC filings FBLG
FibroBiologics, Inc. has 242 filings in SEC EDGAR's recent list, going back to Jan 31, 2023. Its latest annual report, Form ARS, was filed on May 5, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Jul 31, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 8, 2026 (material agreement, new debt, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 19, 2026 | — |
| EFFECT | Filing | Oct 19, 2026 | — |
| D | Filing | Oct 13, 2026 | — |
| D | Filing | Sep 16, 2026 | — |
| EFFECT | Filing | Jul 16, 2026 | — |
| D | Filing | Jun 29, 2026 | — |
| EFFECT | Filing | Mar 31, 2026 | — |
| CORRESP | Letter to the SEC | Mar 27, 2026 | — |
| CORRESP | Letter to the SEC | Mar 27, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 24, 2026 | — |
| DRS | Filing | Mar 20, 2026 | — |
| EFFECT | Filing | Dec 30, 2025 | — |
| CORRESP | Letter to the SEC | Dec 29, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 29, 2025 | — |
| D | Filing | Dec 16, 2025 | — |
| D | Filing | Dec 3, 2025 | — |
| D | Filing | Dec 3, 2025 | — |
| EFFECT | Filing | Feb 10, 2025 | — |
| CORRESP | Letter to the SEC | Feb 6, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 6, 2025 | — |
| EFFECT | Filing | Jan 21, 2025 | — |
| EFFECT | Filing | Jan 14, 2025 | — |
| CORRESP | Letter to the SEC | Jan 10, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2025 | — |
| EFFECT | Filing | Aug 14, 2024 | — |
| EFFECT | Filing | Jun 25, 2024 | — |
| CORRESP | Letter to the SEC | Jun 21, 2024 | — |
| CORRESP | Letter to the SEC | Jun 21, 2024 | — |
| CORRESP | Letter to the SEC | Jun 18, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 17, 2024 | — |
| DRS | Filing | Jun 10, 2024 | — |
| RW | Filing | Jun 6, 2024 | — |
| DRS | Filing | Apr 12, 2024 | — |
| EFFECT | Filing | Mar 28, 2024 | — |
| CORRESP | Letter to the SEC | Mar 27, 2024 | — |
| CORRESP | Letter to the SEC | Mar 26, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 25, 2024 | — |
| CORRESP | Letter to the SEC | Mar 15, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 26, 2024 | — |
| CERT | Filing | Jan 30, 2024 | — |
| EFFECT | Filing | Jan 24, 2024 | — |
| 8-A12B | Filing | Jan 24, 2024 | — |
| CORRESP | Letter to the SEC | Jan 22, 2024 | — |
| CORRESP | Letter to the SEC | Jan 16, 2024 | — |
| CORRESP | Letter to the SEC | Nov 7, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 27, 2023 | — |
| DRSLTR | Filing | Oct 13, 2023 | — |
| DRS/A | Filing | Oct 13, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 11, 2023 | — |
| DRSLTR | Filing | Aug 16, 2023 | — |
| DRS/A | Filing | Aug 16, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 23, 2023 | — |
| DRS | Filing | May 18, 2023 | — |
| C-AR | Filing | May 1, 2023 | Dec 31, 2022 |
| C-U | Filing | Apr 11, 2023 | — |
| C/A | Filing | Mar 29, 2023 | — |
| C/A | Filing | Feb 10, 2023 | — |
| C | Filing | Jan 31, 2023 | — |
Showing 58 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FBLG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1958777
- Former names
- FibroBiologics Inc. (until Feb 6, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.